CVS Health Corporation (NYSE:CVS) – Stock analysts at Oppenheimer Holdings reduced their FY2016 EPS estimates for CVS Health Corporation in a research note issued on Tuesday. Oppenheimer Holdings analyst M. Naidu now anticipates that the firm will post earnings per share of $5.81 for the year, down from their previous forecast of $5.84. Oppenheimer Holdings also issued estimates for CVS Health Corporation’s Q4 2016 earnings at $1.67 EPS, Q1 2017 earnings at $1.33 EPS, Q4 2017 earnings at $1.64 EPS and FY2017 earnings at $5.88 EPS.

A number of other research firms have also recently issued reports on CVS. Deutsche Bank AG lifted their target price on shares of CVS Health Corporation from $99.00 to $108.00 and gave the company a “hold” rating in a research note on Wednesday, August 3rd. Zacks Investment Research upgraded shares of CVS Health Corporation from a “sell” rating to a “hold” rating in a research note on Wednesday, August 3rd. FBR & Co restated an “outperform” rating and issued a $120.00 price objective on shares of CVS Health Corporation in a research report on Wednesday, August 3rd. Argus restated a “buy” rating and issued a $120.00 price objective on shares of CVS Health Corporation in a research report on Thursday, August 4th. Finally, Mizuho boosted their price objective on shares of CVS Health Corporation from $108.00 to $111.00 and gave the stock a “buy” rating in a research report on Thursday, August 4th. Five equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. CVS Health Corporation currently has an average rating of “Buy” and an average price target of $106.24.

Earnings History and Estimates for CVS Health Corporation (NYSE:CVS)

Shares of CVS Health Corporation (NYSE:CVS) opened at 75.09 on Thursday. The firm has a market cap of $80.06 billion, a PE ratio of 17.27 and a beta of 0.88. The stock has a 50 day moving average price of $85.54 and a 200 day moving average price of $93.77. CVS Health Corporation has a 12 month low of $69.30 and a 12 month high of $106.67.

CVS Health Corporation (NYSE:CVS) last issued its earnings results on Tuesday, November 8th. The pharmacy operator reported $1.64 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.57 by $0.07. The business earned $44.60 billion during the quarter, compared to analysts’ expectations of $45.29 billion. CVS Health Corporation had a return on equity of 17.18% and a net margin of 2.96%. CVS Health Corporation’s revenue was up 15.5% compared to the same quarter last year. During the same quarter last year, the firm posted $1.28 earnings per share.

The business also recently announced a quarterly dividend, which was paid on Thursday, November 3rd. Investors of record on Monday, October 24th were paid a $0.425 dividend. This represents a $1.70 dividend on an annualized basis and a yield of 2.26%. The ex-dividend date was Thursday, October 20th. CVS Health Corporation’s payout ratio is presently 36.40%.

Several institutional investors have recently bought and sold shares of CVS. Acrospire Investment Management LLC increased its position in CVS Health Corporation by 542.2% in the second quarter. Acrospire Investment Management LLC now owns 1,066 shares of the pharmacy operator’s stock worth $102,000 after buying an additional 900 shares in the last quarter. MU Investments Co. Ltd. increased its position in CVS Health Corporation by 62.0% in the second quarter. MU Investments Co. Ltd. now owns 1,150 shares of the pharmacy operator’s stock worth $109,000 after buying an additional 440 shares in the last quarter. Pinkerton Retirement Specialists LLC increased its position in CVS Health Corporation by 3,475.0% in the second quarter. Pinkerton Retirement Specialists LLC now owns 1,144 shares of the pharmacy operator’s stock worth $110,000 after buying an additional 1,112 shares in the last quarter. D Orazio & Associates Inc. increased its position in CVS Health Corporation by 9.4% in the second quarter. D Orazio & Associates Inc. now owns 1,160 shares of the pharmacy operator’s stock worth $111,000 after buying an additional 100 shares in the last quarter. Finally, Cantab Capital Partners LLP increased its position in CVS Health Corporation by 355.4% in the second quarter. Cantab Capital Partners LLP now owns 1,184 shares of the pharmacy operator’s stock worth $113,000 after buying an additional 924 shares in the last quarter. Institutional investors own 80.82% of the company’s stock.

CVS Health Corporation Company Profile

CVS Health Corporation, together with its subsidiaries (CVS Health), is a pharmacy company. The Company operates through three business segments: Pharmacy Services, Retail/LTC and Corporate. The Company offers a range of products and services, such as advising patients on their medications at its CVS Pharmacy locations, introducing programs to help control costs for its clients at CVS Caremark, how care is delivered to its patients with conditions through CVS Specialty, pharmacy care for the senior community through Omnicare.

5 Day Chart for NYSE:CVS

Receive News & Stock Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related stocks with our FREE daily email newsletter.